Driving the future of non-surgical endometriosis diagnosis: Hera Biotech acquires Scailyte’s endometriosis diagnostic assets

Basel, Switzerland, January 2024 – By acquiring Scailyte’s endometriosis diagnostic assets, US-based Hera Biotech makes a major advancement in improving diagnosis accuracy and patient care. This consolidation is expected to speed up the creation of clinical tools for diagnosing and stratifying endometriosis patients and facilitate the development of targeted therapies.

2023 Scailyte Hera PressRelease


HEMEX is a global provider of clinical research services to small and medium-sized life sciences companies in diverse therapeutic areas. By combining extensive clinical expertise, commitment to speed, and dedication to patient-centric approaches, HEMEX supports its clients to complete their clinical trials faster. Advancing healthcare and improving patient outcomes, HEMEX’s priority is ensuring patients can have access to lifesaving therapies within a short clinical journey. Through its subsidiaries, Hemex Germany GmbH and Hemex Benelux BV, the company can also secure project funding through different EU funds. For more information, visit https://hemex.ch/